Abstract-The renin-angiotensin system regulates cardiovascular physiology via angiotensin II engaging the angiotensin type 1 or type 2 receptors. Classic actions are type 1 receptor mediated, whereas the type 2 receptor may counteract type 1 receptor activity. Angiotensin-converting enzyme 2 metabolizes angiotensin II to angiotensin-(1-7) and angiotensin I to angiotensin-(1-9). Angiotensin-(1-7) antagonizes angiotensin II actions via the receptor Mas. Angiotensin-(1-9) was shown recently to block cardiomyocyte hypertrophy via the angiotensin type 2 receptor. Here, we investigated in vivo effects of angiotensin-(1-9) via the angiotensin type 2 receptor. Angiotensin-(1-9) (100 ng/kg per minute) with or without the angiotensin type 2 receptor antagonist PD123 319 (100 ng/kg per minute) or PD123 319 alone was infused via osmotic minipump for 4 weeks into stroke-prone spontaneously hypertensive rats. We measured blood pressure by radiotelemetry and cardiac structure and function by echocardiography. Angiotensin-(1-9) did not affect blood pressure or left ventricular mass index but reduced cardiac fibrosis by 50% (PϽ0.01) through modulating collagen I expression, reversed by PD123 319 coinfusion. In addition, angiotensin-(1-9) inhibited fibroblast proliferation in vitro in a PD123 319-sensitive manner. Aortic myography revealed that angiotensin-(1-9) significantly increased contraction to phenylephrine compared with controls after N-nitro-L-arginine methyl ester treatment, an effect abolished by PD123 319 coinfusion (area under the curve: angiotensin-(1-9) N-nitro-L-arginine methyl esterϭ98.9Ϯ11.8%; controlϩN-nitro-Larginine methyl esterϭ74.0Ϯ10.4%; PϽ0.01), suggesting that angiotensin-(1-9) improved basal NO bioavailability in an angiotensin type 2 receptor-sensitive manner. In summary, angiotensin-(1-9) reduced cardiac fibrosis and altered aortic contraction via the angiotensin type 2 receptor supporting a direct role for angiotensin-(1-9) in the reninangiotensin system. (Hypertension. 2012;59:300-307.) • Online Data Supplement Key Words: renin-angiotensin system Ⅲ angiotensin-(1-9) Ⅲ cardiac fibrosis Ⅲ angiotensin type 2 receptor Ⅲ stroke-prone spontaneously hypertensive rat A ngiotensin II (Ang II) is the main effector of the renin-angiotensin system (RAS), classically acting via the angiotensin type 1 receptor (AT 1 R) to stimulate effects such as sodium reabsorption, vasoconstriction, proliferation, and inflammation. Ang II, acting via the AT 1 R, contributes to the pathophysiology of cardiovascular disease. The angiotensin type 2 receptor (AT 2 R) is 34% homologous to the AT 1 R, 1 and its actions differ. 2,3 AT 2 R expression is limited to fetal/neonatal tissues 4 ; however, in adult rodents it is upregulated in heart failure and postmyocardial infarction. 5 In human adult myocardium, 41% of angiotensin binding sites are AT 2 Rs. 5 Ang II signaling via the AT 2 R counteracts AT 1 R signaling; for example, blocking AT 2 R activation promotes cardiomyocyte hypertrophy, 2 whereas AT 2 R overexpression in stroke-prone spontaneously hypertensive rat (SHRSP) hearts prevents increased left ventricular mass index (LVMI). 6 Transgenic overexpression of the AT 2 R in mice reduces cardiac fibrosis. 3 Furthermore, the bradykinin B 2 receptor associates with the AT 2 R, inhibiting fibrosis and promoting vasodilatation through endothelial NO synthase. 3, 7 Stimulating the AT 2 R with the oral agonist C21 postmyocardial infarction diminishes interleukin 6, interleukin 1␤, and interleukin 2 expression and reduces scar size. 8 The angiotensin-converting enzyme (ACE) homologue ACE2 is an additional important RAS member with different enzymatic activity, substrate specification, and inhibitor specificity. 9 ACE2 metabolizes angiotensin I and Ang II to form angiotensin 1-9 (Ang-[1-9]) and angiotensin 1-7 (Ang-[1-7]), respectively. 10 Ang-(1-9) is also metabolized by ACE to Ang-(1-7). 11 In the heart, vasculature, and kidneys, Ang-(1-7)
A ngiotensin II (Ang II) is the main effector of the renin-angiotensin system (RAS), classically acting via the angiotensin type 1 receptor (AT 1 R) to stimulate effects such as sodium reabsorption, vasoconstriction, proliferation, and inflammation. Ang II, acting via the AT 1 R, contributes to the pathophysiology of cardiovascular disease. The angiotensin type 2 receptor (AT 2 R) is 34% homologous to the AT 1 R, 1 and its actions differ. 2, 3 AT 2 R expression is limited to fetal/neonatal tissues 4 ; however, in adult rodents it is upregulated in heart failure and postmyocardial infarction. 5 In human adult myocardium, 41% of angiotensin binding sites are AT 2 Rs. 5 Ang II signaling via the AT 2 R counteracts AT 1 R signaling; for example, blocking AT 2 R activation promotes cardiomyocyte hypertrophy, 2 whereas AT 2 R overexpression in stroke-prone spontaneously hypertensive rat (SHRSP) hearts prevents increased left ventricular mass index (LVMI). 6 Transgenic overexpression of the AT 2 R in mice reduces cardiac fibrosis. 3 Furthermore, the bradykinin B 2 receptor associates with the AT 2 R, inhibiting fibrosis and promoting vasodilatation through endothelial NO synthase. 3, 7 Stimulating the AT 2 R with the oral agonist C21 postmyocardial infarction diminishes interleukin 6, interleukin 1␤, and interleukin 2 expression and reduces scar size. 8 The angiotensin-converting enzyme (ACE) homologue ACE2 is an additional important RAS member with different enzymatic activity, substrate specification, and inhibitor specificity. 9 ACE2 metabolizes angiotensin I and Ang II to form angiotensin 1-9 (Ang- [1] [2] [3] [4] [5] [6] [7] [8] [9] ) and angiotensin 1-7 (Ang- [1] [2] [3] [4] [5] [6] [7] ), respectively. 10 Ang-(1-9) is also metabolized by ACE to Ang-(1-7). 11 In the heart, vasculature, and kidneys, Ang- (1) (2) (3) (4) (5) (6) (7) blocks detrimental effects of Ang II via the receptor Mas. 12 For example, Ang-(1-7) blocks Ang II-induced fibrosis, cardiac hypertrophy, and hypertension 13 and in the heart reduces re-entrant arrhythmias. 14 Ang-(1-7) reverses Ang II-induced endothelial dysfunction via Mas-mediated stimulation of endothelial NO synthase. 15 Ang-(1-9) is thought to reduce Ang II levels because it competes with angiotensin I at the ACE active site and increases Ang-(1-7) and stimulates bradykinin release in endothelial cells. 16 Recently Ang-(1-9) was demonstrated to inhibit cardiac hypertrophy after myocardial infarction in rats. 17 This was not dependent on Ang-(1-9) to Ang-(1-7) conversion, because coadministration of the Mas antagonist A779 did not influence the effects of Ang-(1-9). However, Ang-(1-9) administration did lead to decreased Ang II levels. Moreover, we have shown recently that Ang-(1-9) is able to compete with Ang II binding at the AT 2 R via radioligand binding assay and is able to block cardiomyocyte hypertrophy in vitro. Furthermore, inhibition of hypertrophy by Ang-(1-9) is blocked in the presence of the selective AT 2 R inhibitor PD123 319. 18 Here, we have infused Ang-(1-9) into a model of essential hypertension, the SHRSP, to investigate its effects on blood pressure, cardiac remodeling and function, and vascular function and whether they are mediated via the AT 2 R.
Methods
For the methods section for this article please see the online Data Supplement at http://hyper.ahajournals.org.
Results

Effects of Ang-(1-9) on Blood Pressure
Averaged weekly telemetric blood pressure readings were analyzed. All 4 of the groups (nϭ6) started with similar values of mean arterial blood pressure (control: 155.8Ϯ1.6 mm Hg; Ang-(1-9): 153.9Ϯ3.6 mm Hg; Ang-(1-9)ϩPD123 319: 156.2Ϯ2.2 mm Hg; PD123 319: 150.6Ϯ 2.4 mm Hg; Figure 1 ). Two weeks after minipump implantation, mean arterial blood pressure increased in Ang-(1-9), Ang-(1-9)ϩPD123 319, and PD123 319 animals compared with control, although it did not reach statistical significance when comparing groups or when comparing the 4-week end point within a group to measurements at the point of minipump implantation (13 weeks 
Effects of Ang-(1-9) on Cardiac Function
Baseline measurements between groups at the start of the study did not differ (data not shown). Analysis of echocardiographs at both 2 and 4 weeks after minipump implantation (15 and 17 weeks of age) revealed that LVMI normalized through tibia length was not different between groups (control: 1.8Ϯ0.1 mm; Ang-[1-9]: 1.9Ϯ0.1 mm; Ang-(1-9)ϩPD123 319: 1.8Ϯ0.1 mm; PD123:319: 1.7Ϯ0.5 mm; Table S1 , available in the online Data Supplement). Extrapolation of data from the echocardiographs showed no significant difference in cardiac output, stroke volume, fractional shortening, or ejection fraction between groups (Table S1 ). Calculation of early/atrial ratio as an indirect indicator of diastolic function also revealed no significant differences between groups ( Figure S1 ).
Effects of Ang-(1-9) on Endothelial Function
Aortic wire myography was used to evaluate the effect of Ang-(1-9) on endothelial function. Carbachol induced relaxation in all of the groups confirming functional integrity of the endothelium of the aortic rings because there were no significant differences between any of the groups ( Figure S2 ). In control SHRSPs, inhibition of endothelial NO synthase with N G -nitro-L-arginine methyl ester (L-NAME) did not modify basal arterial tension induced by phenylephrine (PE) because there was no significant difference between the contraction curves (control PE: 64.1Ϯ10.3% of maximal contraction; control PEϩL-NAME: 74.0Ϯ10.4%, area under the curve; Figure 2 ). This indicated reduced basal NO availability in the control animals, consistent with other SHRSP studies. 19 In Ang-(1-9)-infused animals L-NAME significantly increased contractile response, inducing a 30% Rat's Age (weeks) Figure 1 . Effects of angiotensin (Ang)-(1-9) infusion on blood pressure in stroke-prone spontaneously hypertensive rat (SHRSP). Blood pressure was monitored via radiotelemetry from 11 weeks of age, and mean arterial pressure is shown. Infusion of either water (control), Ang-(1-9), Ang-(1-9)ϩPD123 319, or PD123 319 was initiated at 13 weeks of age for 4 weeks. Two-way ANOVA was performed, and no significant difference between groups was found. nϭ6 rats per group.
difference between the curves (Ang-(1-9) PE: 68.3Ϯ10.8%; Ang-(1-9) PEϩL-NAME: 98.9Ϯ11.8; PϽ0.01; Figure 2 ), indicating that Ang-(1-9) improved NO bioavailability. In contrast, animals coinfused with Ang-(1-9) and PD123 319 showed no difference between basal and PEϩL-NAME contraction (Ang-(1-9)ϩPD123 319 PE: 62.2Ϯ10.8%; Ang-(1-9)ϩPD123 319 PEϩL-NAME: 72.5Ϯ17.7%), indicating that PD123 319 abrogated effects of Ang-(1-9) on endothelial function ( Figure 2 ). PD123 319 alone had no effect on endothelial function. Next, we analyzed expression of the reactive oxygen species-generating enzyme NADPH oxidase 4 in aortas by immunohistochemistry ( Figure 2 ). Ang-(1-9) produced a significant increase in aortic NADPH oxidase 4 expression (PϽ0.05) compared with control rats, which was abolished in the presence of PD123 319.
Histological Assessment of Ang-(1-9) Effects in the Heart
There was no obvious evidence of irregularity in cardiac structure between groups by hematoxylin and eosin staining Effects of angiotensin (Ang)-(1-9) infusion on endothelial function. Large-vessel myography was performed in aortic rings from stroke-prone spontaneously hypertensive rats (SHRSPs) infused with water (control; A), Ang-(1-9) (B), Ang-(1-9)ϩPD123 319 (C), or PD123 319 alone (D) for 4 weeks. Basal contractile response was induced by phenylephrine (PE) and endogenous production of NO inhibited with N G -nitro-L-arginine methyl ester (L-NAME) before inducing contraction with PE. Endothelial function was evaluated by NO bioavailability, which was assessed as the difference between contractile response curves. *PϽ0.0001; nϭ6 animals per group. E, NADPH oxidase 4 (NOX4) expression in aortas of SHRSPs infused with water (control), Ang-(1-9), Ang-(1-9)ϩPD123 319 (PDϩAng1-9), or PD123 319 alone for 4 weeks was assessed by immunohistochemistry and quantified using Image-ProPlus. #PϽ0.05 vs control. Scale barϭ50 m, top panel magnification: ϫ20; bottom panel magnification: ϫ40.
( Figure 3A ). Masson trichrome in control SHRSPs revealed significant collagen staining in the perivascular region (Figure 3B) , whereas perivascular fibrosis was attenuated in SHRSPs infused with Ang-(1-9), suggesting that it blocked fibrosis development. Interestingly, after coinfusion of PD123 319 and Ang-(1-9), quantification of cardiac fibrosis was similar to that observed in control animals; however, the distribution of staining in PD123 319 and Ang-(1-9)-infused animals was altered as interstitial fibrosis was observed, as opposed to the predominantly perivascular staining in control and PD123 319 alone animals ( Figure 3B ). Picrosirius red staining of control hearts revealed increased perivascular and interstitial deposits of collagen fibers, which was blocked by Ang-(1-9) infusion in a PD123 319-sensitive manner ( Figure   3C ). Similar to what was observed with Picrosirius red staining, immunohistochemical staining of collagen Ia fibers showed a significant reduction in SHRSPs infused with Ang-(1-9), an effect that was reversed when Ang-(1-9) was coinfused with PD123 319 (Figure 4A and 4B). However, no significant difference between groups was observed for collagen IIIa fibers ( Figure 4B through 4D) . Myocardial mRNA expression of tissue inhibitor of metalloproteinase 1, tissue inhibitor of metalloproteinase 2, and matrix metalloproteinase (MMP) 2 showed no significant difference between groups ( Figure S3 ). However, a significant increase in MMP-14 gene expression was observed in SHRSP hearts infused with PD123 319 alone. Gene expression levels of MMP-9 were undetectable in all of the groups. 
In Vitro Proliferation Assays in Cardiac Fibroblasts
To confirm direct effects of Ang-(1-9) on fibroblast phenotype, isolated primary cultures of neonatal fibroblasts were assessed. Coaddition of Ang-(1-9) to 5% serum-stimulated fibroblasts inhibited proliferation ( Figure 5 ). However, the addition of PD123 319 to Ang-(1-9)-stimulated fibroblasts reversed the antiproliferative effect of Ang-(1-9) ( Figure 5A ). Quantification of collagen Ia and IIIa expression by quantitative RT-PCR revealed that Ang-(1-9) induced significant downregulation of collagen Ia, but not IIIa, an effect prevented by coaddition of PD123 319 ( Figure 5B ). These results demonstrated that Ang-(1-9) was able to mediate antiproliferative effects on fibroblasts via the AT 2 R.
Discussion
Previously we have shown that regression of increased LVMI in the SHRSP can be achieved via AT 1 R antagonism or mitochondrial-targeted antioxidants. 20 -22 Here, SHRSPs were used to study the effects of Ang-(1-9) on blood pressure, cardiac structure and function, and endothelial function via the AT 2 R. SHRSPs were infused with Ang-(1-9), Ang-(1-9)ϩPD123 319, or PD123 319 alone via osmotic minipump. Ang-(1-9) infusion had no significant effect on blood pressure, cardiac function, or LVMI; however, Ang-(1-9) reduced cardiac fibrosis and improved NO bioavailability ( Figure 6 ). Importantly, PD123 319 reversed the effects of Ang-(1-9), suggesting that its actions were mediated by the AT 2 R.
The RAS is the main regulator of systemic blood pressure. In animal models, systemic delivery of Ang II induces increased blood pressure and cardiac remodeling. 23, 24 Novel components of the "counterregulatory" RAS have been shown to mediate beneficial effects on blood pressure and cardiac remodeling, for example, ACE2 and Ang-(1-7) have both been shown to reduce cardiac hypertrophy and fibrosis, as well as to lower blood pressure. 25, 26 Ang-(1-9) is a metabolite of ACE2 from angiotensin I and can also be converted to Ang-(1-7) by ACE. 27 Ang-(1-9) has been described previously to potentiate bradykinin release in endothelial cells isolated from cardiac tissue, 16 which may explain the increased NO bioavailability observed in our study. Alternatively, Ang-(1-9) may enhance endothelial NO synthase activation, as has been described for Ang-(1-7). 15 Because NO is a vasodilatator agent that can decrease vascular resistance, Ang-(1-9) may reduce vascular resistance by improving endothelial function attributed to increased basal NO bioavailability. Interestingly, when Ang-(1-9)-infused SHRSPs were coinfused with the AT 2 R antagonist PD123 319, vasorelaxation/NO bioavailability decreased to the levels of control animals. This further supports a role for Ang-(1-9) acting via the AT 2 R. In support of our findings, AT 2 R stimulation has been described to increase synthesis of NO in cardiac endothelial cells promoting vasodilatation. 7 Our PE and carbachol relaxation curves suggest that we have not stimulated NO release but that Ang-(1-9) may increase basal NO bioavailability. Furthermore, it was shown recently that transgenic NADPH oxidase 4 overexpression in murine endothelium promoted vasodilatation through hydrogen peroxide release, an effect independent of NO activity. 28 In our study, Ang-(1-9) infusion also significantly increased aortic NADPH oxidase 4 expression in a PD123 319-sensitive manner, an interesting finding suggesting that Ang-(1-9) may influence vascular function via multiple mechanisms and important to further investigate in future studies. Interestingly, although we observed improved vasorelaxation through Ang-(1-9) infusion, we did not observe significant -(1-9) ), or PD123 319 alone was assessed by immunohistochemistry and quantified using ImageProPlus. Scale barϭ10 m. Magnification: ϫ20. *PϽ0.05 vs control animals.
changes in blood pressure. Furthermore, there was a tendency for animals infused with Ang-(1-9) to have higher blood pressure, although only longer-term studies would reveal whether this reached significance. Previously, lentiviral overexpression of the AT 2 R in spontaneously hypertensive rat hearts did not affect blood pressure, 6 and transgenic cardiacselective AT 2 R overexpression did not affect blood pressure or cardiac hypertrophy compared with wild-type mice; however, it did reduce cardiac fibrosis. 29 Here, coinfusion of Ang-(1-9) and the AT 2 R antagonist PD123 319 also appeared to invoke redistribution of fibrosis from perivascular sites to the interstitium. In both Ang-(1-9) and PD123 319 and PD123 319 alone groups, increased collagen I staining compared with control animals was observed. Furthermore, PD123 319 infusion alone increased MMP-14 gene expression. This is consistent with previous observations regarding endogenous AT 2 R function. Infusion of PD123 319 in a rat model of glomerulosclerosis induced by 5/6 nephrectomy significantly increased glomerular cell proliferation and kidney fibrosis compared with animals that were nephrectomized alone. 30 Increased collagen I levels have also been shown previously to upregulate MMP-14 expression at the mRNA level, 31 which supports our findings. Moreover, fibrotic tissue remodeling after injury is associated with vascular damage and leakage, which has been shown to be associated with type I collagen remodeling and increased MMP-14 activity in mouse models of age-related dermal fibrosis. 32 We demonstrated recently that Ang-(1-9) was able to block cardiomyocyte hypertrophy in vitro in both adult and neonatal cardiomyocytes, an effect that was mediated via the AT 2 R and not via Mas and was distinguishable from the effects of Ang-(1-7) that did act via Mas. 18 Furthermore, Ocaranza et al 17 demonstrated that Ang-(1-9) also prevented cardiomyocyte hypertrophy in a rat myocardial infarction model. In that model, preventing cardiomyocyte hypertrophy was also not dependent on Ang-(1-9) increasing Ang-(1-7) activity via Mas, because the Mas antagonist A779 had no effect but was thought to be through Ang-(1-9) binding ACE and preventing Ang II generation. Both of these articles suggest that Ang-(1-9) actions are independent of conversion to Ang- (1-7) by ACE. Moreover, our lack of effect on cardiac hypertrophy is consistent with previous effects of AT 2 R signaling. 29 In SHRSPs aged 12 weeks, hypertension and increased LVMI are well established, 21 although SHRSPs only develop increased LVMI as a compensatory response to increased afterload and do not develop heart failure until Ϸ2 years of age and, therefore, have normal cardiac function. 33, 34 Here, this is supported by calculation of early/atrial ratio, which indicated normal diastolic function. Although early/atrial ratio is an indirect analysis of diastolic function and use of pressure-volume loop catheters in future studies would accurately assess diastolic function. However, in the SHRSPs, Ang-(1-9) was able to block development of cardiac fibrosis, an effect that was blocked by coinfusion with PD123 319. These data further support a role for the AT 2 R, because other studies support an antifibrotic role for the AT 2 R without affecting cardiac hypertrophy or systemic blood pressure. 35, 36 Although circulating Ang-(1-9) levels are low, in heart failure patients the myocardium forms 1 nmol/L ⅐ min Ϫ1 ⅐ mg
Ϫ1
Ang-(1-9), and the heart contains 170 nmol/L of Ang I, with 85% converted to equivalent levels of Ang-(1-9) and Ang II, supporting a potential role for Ang-(1-9) in human cardiovascular disease by potentially acting at the AT 2 R to counteract detrimental effects of Ang II at the AT 1 R. 37 With evidence that Ang-(1-9) is a functional agonist at the AT 2 R, this has important translational implications for understanding and developing new therapeutic avenues in cardiovascular disease.
Perspectives
We show a direct in vivo role for Ang-(1-9) acting via the AT 2 R to reduce cardiac fibrosis and improve endothelial function in the SHRSP. These findings suggest that Ang-(1-9), a relatively unexplored peptide of the RAS, may be an additional member of the increasingly important counterregulatory RAS and, like Ang-(1-7), an important target in our understanding of cardiovascular disease and in identifying novel therapeutic targets.
Methods
Animals
The stroke prone spontaneously hypertensive rat (SHRSP) are maintained "in-house" by brother-sister mating and microsatellite and single nucleotide polymorphism genotyping is routinely performed to confirm homozygosity of all screened loci. All animals were housed under 12h light/dark cycles at ambient temperature, fed standard rat chow (Rat and Mouse No 1, Special Diet Servcies) and water provided ad libitum. Male rats were used. All studies in experimental animals were in accordance with the Animals Scientific Procedures Act 1986 and all studies were approved by the University of Glasgow's Ethics Review Committee. 6 animals were used for each group, 24 in total.
Surgical Procedures
For radiotelemetry probe and osmotic minipump implantation rats were anesthetized with 2.5% isofluorane in 1.5 L/min O 2 for the duration of the surgical implantation procedure. Carprofen (5mg/kg), a Non-Steroidal Anti-inflammatory analgesic is administered immediately prior to surgery. For transthoracic echocardiography SHRSP were mildly anaesthetized with 1.25% to 1.5% isoflurane in 1.5 L/min O 2 before image acquisition and were positioned in left lateral decubitus on a heated pad. Radiotelemetry Hemodynamics of SHRSP were monitored using the Dataquest IV (Art Gold) Radiotelemetry System (Data Science International, Minnesota, USA). Eleven week old SHRSP were anesthetised with isoflurane and the transmitter inserted into the abdominal aorta as previously described 1 . Rats were housed in individual cages following the procedure. Ten days later osmotic minipumps (Alzet, CA, USA) were subcutaneously implanted to secrete Ang-(1-9) (Phoenix Pharmaceuticals, Burlingame, CA, USA) (100ng -1 kg -1 min -1 ) +/-the AT 2 R blocker PD123,319 (Sigma Aldrich, Poole, Dorset, UK) (100ng -1 kg -1 min -1 ) for 4 weeks. Control SHRSP were implanted with a minipump secreting dH 2 O. At the end of the protocol rats were sacrificed and tissues harvested for myography, histology and Q-RT-PCR. Echocardiography Three echocardiograms were performed at 11, 15 and 17 weeks of age. An Acuson Sequoia c512 ultrasound system was used to acquire non-invasive 2-D guided M-mode images at a depth of 20 mm and at the tip of the papillary muscles which were measured in a short axis view using the leading edge-to-lead edge convention during both systole and diastole over at least three consecutive cardiac cycles. 
